CHRISTUS expands its footprint in South Central Texas with the acquisition of Central Texas Medical Center.
AdventHealth will transfer ownership of the 170-bed Central Texas Medical Center in San Marcos, Texas to CHRISTUS Health, the health systems announced Monday.
Financial terms were not disclosed for the deal, which is expected to be finalized this spring after clearing regulatory hurdles.
"The addition of CTMC to our family of hospitals further demonstrates our commitment to keeping exceptional health care close to home," CHRISTUS President and CEO Ernie Sadau said in a media release. "With hospitals in San Antonio, New Braunfels and now San Marcos we are better positioned to serve all in the rapidly growing communities in South and Central Texas."
AdventHealth President and CEO Terry Shaw said the transfer was in the best interests of the hospital and the community it serves.
"Over time we’ve realized that the interests of CTMC and the community it serves would benefit from the hospital joining a strong health system with a robust regional network," Shaw said.
Irving, Texas-based CHRISTUS Health, a Catholic, not-for-profit, includes more than 60 hospitals and long-term care facilities, and more than 175 outpatient clinics and other care sites in Texas, Arkansas, Louisiana and New Mexico and internationally in Chile, Colombia and Mexico.
Not-for-profit, Altamonte Springs, Florida-based AdventHealth, which is sponsored by the Seventh-day Adventist Church, employs more than 80,000 people and operates 45 hospitals, 15 skilled nursing facilities, and 36 urgent care centers in nine states.
“With hospitals in San Antonio, New Braunfels and now San Marcos we are better positioned to serve all in the rapidly growing communities in South and Central Texas.”
Ernie Sadau, CEO, CHRISTUS Health
John Commins is the news editor for HealthLeaders.
KEY TAKEAWAYS
AdventHealth President and CEO Terry Shaw said the transfer was in the best interests of the hospital and the community it serves.
Financial terms were not disclosed for the deal, which is expected to be finalized this spring after clearing regulatory hurdles.